Urine test may identify human papillomavirus accurately
the ONA take:
According to a new study published in The BMJ, researchers say a urine screening may be accurate at identifying human papillomavirus (HPV). In the study, researchers analyzed 14 studies that tested both the Papanicolaou (Pap) smear test and a urine test to test for HPV in nearly 1,500 sexually active women.
The researchers found that the sensitivity of urine HPV screening was 87% on average and specificity was 94% versus a Pap smear. When researchers only looked at identifying HPV types 16 and 18, the strains that cause cervical cancer and which Gardasil protects against, sensitivity was 73% while specificity was 98%. Researchers note that urine HPV testing accuracy improved when a patient's first-void, first urine sample of the day, was used.
The researchers suggest that urine testing for HPV may be an acceptable alternative to a Pap smear, especially for those who require increased coverage for subgroups that are difficult to reach; however, they also note that there was variation between individual studies, and therefore, the results should be interpreted with caution. Further studies are warranted before urine testing for HPV should be recommended in the clinical setting.
Researchers say a urine screening may be accurate at identifying HPV.
The most common screening method for human papillomavirus (HPV) is a Papanicolaou (Pap) test, also known as a smear test. This involves a doctor or nurse scraping cells from the opening of a woman's cervix, before sending them to a laboratory to be analyzed for abnormalities.
The American Cancer Society claim that between 1955 and 1992, death rates from cervical cancer fell by almost 70% due to increased Pap testing. But despite this success, screening uptake in recent years has been low.
Sign Up for Free e-newsletters
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
- Urine Drug Testing Policy Can Assist Opioid Treatment Decisions
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|